Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Van Morris, MD
CONTACT
Lead
M.D. Anderson Cancer Center
With
Primary Objectives To evaluate the overall response rate for Sacituzumab tirumotecan in participants with treatment refractory unresectable and/or metastatic anal cancer. Secondary Objectives * To estimate progression-free survival for Sacituzumab tirumotecan in participants with treatment refractory unresectable and/or metastatic anal cancer. * To describe the disease control rate using criteria for Sacituzumab tirumotecan in participants with treatment-refractory unresectable and/or metastatic anal cancer. * To summarize safety and tolerability using CTCAE version 5.0 for Sacituzumab tirumotecan in participants with treatment-refractory unresectable and/or metastatic anal cancer.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted